




Incorporating Real-World Evidence into Cancer Drug Funding Decisions in Canada:

A Qualitative Study of Stakeholders' Perspectives

Marc Clausen,
Li Ka Shing Knowledge Institute
St. Michael's Hospital

RESEARCH TEAM



Project Leads:

Yvonne Bombard, Li Ka Shing Knowledge Institute, St. Michael's Hospital,

Kelvin Chan, Sunnybrook Odette Cancer Centre

Study Team

- Marc Clausen, Li Ka Shing Knowledge Institute, St. Michael's Hospital
- Chloe Mighton, Li Ka Shing Knowledge Institute, St. Michael's Hospital
- Ruhi Kiflen, Li Ka Shing Knowledge Institute, St. Michael's Hospital
- Wei Fang Dai, CancerCare Ontario
- Rebecca Mercer, CancerCare Ontario
- Jaclyn Beca, CancerCare Ontario
- Wanrudee Isaranuwachai, Li Ka Shing Knowledge Institute, St. Michael's Hospital


The team has no conflicts of interest to disclose



St. Michael's
Inspired Care.
Inspiring Science.

Cancer Drug Funding and Real World Evidence (RWE)

RWE: Data gathered outside of RCT in real world setting (admin data, registries, etc)



Can REValue

Value-based decisions from Real World Evidence

Objective: Collaboration to develop a framework for the generation and use of Real-World Evidence for cancer drug funding decisions in Canada

Phase One: Understand Current State of RWE in Canada

AIMS AND METHODS


Aim

Explore stakeholders' views regarding the development and implementation of a framework to incorporate RWE in cancer drug funding decisions in Canada

Methods

- Semi-structured interviews (in person / phone)
 - Pan-Canadian and international sample of stakeholders
 - Convenience / Snowball Sample
 - Thematic analysis
-

Results



N=30


April – December 2018

Atlantic, Central, Prairies, West Coast

Stakeholders:

- Decision-makers
- Academics
- Industry
- Patient group representatives
- International users

Results



Culture Shift

- Enthusiasm
- Close RCT evidence gaps / shortcomings
- Delisting, renegotiations, supporting current drug funding

However...

“

- RCTs gold standard

“I guess it's just easier with randomized controlled trials, because I think the approach and the accepted analytical methods are much better known. And there's a lot more debate, and I guess uncertainty about what the best methods would be in real world evidence because there's so many variables. I'm not sure that there's one way. It creates a situation where it's easy to criticize any analysis that's done.” -#014

A shift in culture on the use of non RCT generated data: Accept risks inherent to RWE

Current State of Data

Current Data Insufficient for Decision-Making



Collection:

- Incomplete (“patchy”) datasets
- Varied data collection practices
- Lacking key decision-making measures?

Access:


- limited / time and resource intensive / Privacy vs. access

“I also think that there’s still a scarcity of data, that we don’t have data for everything yet. We have a lot of data, but it seems to be unorganized and lack of consistency of how people are gathering data. So, until we really can get our data together, and that it’s shared, it’s consistent, it’s gathered in the same way, and it’s pool-able, until that is done I think it can be challenging to really use the data” -

#010

Building Capacity


Need for Investment in Building Capacity



- Few with RWE experience in public setting
- Requires time and cost intensive investment (staff, systems, etc). Who Pays?




- Who leads?
“So it’s a kind of problematic issue right now to be pursuing real world evidence based agreements for too many products because they’re very complex and it takes a long time and it takes a lot of resources because capacity is very stretched” -#07



Need for Collaboration

Increase Collaboration Among Stakeholders



Systems currently operating in “silos”:

- Clinicians, patients, industry, policy-makers
- Leads to duplication, inefficiencies

“

Public / Industry Relations:

- Hesitant
 - Opportunity to improve relations
 - Industry will need to have a role in RWE
- “If you're going to do these studies, there has to be a change in the attitudes between the players. Like, the payers, government, and cancer agencies, typically don't have a really good relationship with industry...only if you have that kind of collaborative environment, would you actually be able to undertake some of these studies efficiently and effectively.” - #002


RWE an opportunity to evolve how stakeholders work together: revisit collaboration with industry?



• Opportunities for Implementation •


Leverage

- Perceived value of RWE
- Systems transformation



Demonstrate

- Address gaps in understanding of how RWE is operationalized



Clarify

- Provide transparency on what has already been achieved
- Clarify perceived barriers that will not actually impact adoption

